Acquired Company
AstraZeneca completed its acquisition of CinCor Pharma on 2/24/2023 for approximately $1.3 billion upfront plus up to $500 million in contingent value rights, for a total potential value of about $1.8 billion.
CinCor Pharma Inc. is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. The companys focus is on cardiovascular, metabolic and kidney diseases. CinCor Pharma was founded by Jon Isaacsohn, M.D., and Catherine Pearce, DHSc, MBA, in 2018. Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$29.06
Open
$29.06
Volume
N/A
Day Range
$29.06 - $29.06
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
12.00%
Institutional Own.
94.12%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|